StocksMedium•13 October 2026•
1 min read
Zealand Pharma and Generate Biomedicines Partner for $1.2B AI-Driven Obesity Drug Deal
Key Facts
1Generate Biomedicines will receive $30 million upfront and up to $1.2 billion in total milestone payments.
2The collaboration aims to use a generative AI platform to develop protein therapeutics for metabolic diseases and obesity.
Zealand Pharma and Generate Biomedicines have signed a collaboration and license agreement to develop AI-engineered protein therapeutics for metabolic diseases, specifically targeting obesity. GlobeNewswire reported that Generate Biomedicines will receive $30 million upfront and is eligible for total milestone payments of up to $1.2 billion.
The partnership aims to combine Zealand Pharma's peptide expertise with Generate's generative AI platform to create multi-specific drug candidates. In equity markets, ZLDPF closed at $34.87 on October 12, 2026, while GENB closed at $13.84 on the same date.